AbbVie Completes Acquisition of Landos Biopharma
Provided By PR Newswire
Last update: May 23, 2024
- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Read more at prnewswire.com202.08
+1.2 (+0.6%)
Find more stocks in the Stock Screener
ABBV Latest News and Analysis
20 days ago - ChartmillExploring the top movers within the S&P500 index during today's session.Let's delve into the developments on the US markets one hour before the close of the markets on Monday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
20 days ago - ChartmillTop S&P500 movers in Monday's sessionStay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
